{"organizations": [], "uuid": "a81a4fe1213f8de42af2b9555e431c74509c53d5", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/6", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/04/04/globe-newswire-bradmer-announces-fourth-quarter-and-full-year-2017-financial-results.html", "country": "US", "domain_rank": 767, "title": "Bradmer Announces Fourth Quarter and Full Year 2017 Financial Results", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-05T00:00:00.000+03:00", "replies_count": 0, "uuid": "a81a4fe1213f8de42af2b9555e431c74509c53d5"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/04/04/globe-newswire-bradmer-announces-fourth-quarter-and-full-year-2017-financial-results.html", "ord_in_thread": 0, "title": "Bradmer Announces Fourth Quarter and Full Year 2017 Financial Results", "locations": [], "entities": {"persons": [], "locations": [{"name": "toronto", "sentiment": "none"}], "organizations": [{"name": "bradmer pharmaceuticals inc.", "sentiment": "negative"}, {"name": "tsx venture", "sentiment": "negative"}, {"name": "company", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "TORONTO, April 04, 2018 (GLOBE NEWSWIRE) --\nBradmer Pharmaceuticals Inc. (TSX VENTURE:BMR.H) (“Bradmer” or the “Company”) today announced its fourth quarter and full year 2017 financial results.\nFinancial Results\nAmounts in US dollars, unless specified otherwise, and results prepared in accordance with International Financial Reporting Standards (“IFRS”).\nFor the three months ended December 31, 2017, the Company recorded a net loss of $74,000 or $0.004 per common share based on the weighted average outstanding shares of 19,659,726 during the three-month period, compared to a net loss of $21,000 or $0.001 per common share for the quarter ended December 31, 2016 based on the same shares outstanding.\nGeneral and administrative expenses were $75,000 in the three months ended December 31, 2017 compared to $31,000 in the same quarter of the prior year. Major expenses in 2017 consisted of consulting fees of $14,000, directors’ and officers’ liability insurance premiums of $2,000, audit fees of $2,000 and legal fees of $54,000. In 2016 major expenses consisted of consulting fees of $13,000, directors’ and officers’ liability insurance premiums of $2,000, audit fees of $2,000 and legal fees of $8,000.\nThe $1,000 foreign exchange gain in the fourth quarter of 2017 compared with a $10,000 foreign exchange gain in the same quarter of 2016.\nFor the year ended December 31, 2017, we recorded a net loss of $184,000 or $0.009 per common share based on the weighted average outstanding shares of 19,659,726 during the period, compared to a net loss of 136,000 or $0.007 per common share for the year ended December 31, 2016 based on the weighted average outstanding shares of 19,659,726.\nGeneral and administrative expenses were $160,000 in the year ended December 31, 2017 compared to $123,000 in the prior year. Major expenses in 2017 consisted of consulting fees of $55,000, legal fees of $72,000, insurance premiums of $10,000, audit fees of $10,000 and transfer agent and stock exchange listing fees of $8,000. Major expenses in 2016 consisted of consulting fees of $54,000, legal fees of $32,000, insurance premiums of $10,000, audit fees of $10,000 and transfer agent and stock exchange listing fees of $12,000.\nThe $24,000 foreign exchange loss in 2017 compared with a $12,000 foreign exchange loss in 2016.\nThe main reason for the increased net loss in 2017 is due to the $40,000 increase in legal fees.\nBradmer’s operational activities for the year ended December 31, 2017 were financed by cash on hand. At December 31, 2017, the Company had working capital of $218,000, compared to $382,000 at December 31, 2016. Bradmer had available cash of $319,000 (CDN $400,000) as at December 31, 2017, compared to cash of $414,000 (CDN $556,000) as at December 31, 2016. The $95,000 decrease in cash was due to the $184,000 net loss partially offset by the $69,000 decrease in non-cash working capital and the $20,000 of foreign currency adjustments.\nAs at April 3, 2018 and December 31, 2017, the Company had 19,659,726 common shares and options to purchase 1,950,000 common shares outstanding.\nBradmer Pharmaceuticals Inc.\nPaul Van Damme\nChief Financial Officer\npvandamme@wdcapital.ca\n1.416.847.6905\nAdditional information about Bradmer, including the MD&A and financial results may be found on SEDAR at www.sedar.com .\nNEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.\nBradmer's common shares have not been registered under the Securities Act of 1933, as amended (the \"Securities Act\") or any state regulatory agency in the United States. The resale or transfer by a U.S. investor of such common shares of Bradmer Pharmaceuticals Inc. is subject to the requirements of Rule 904 of Regulation S of the Securities Act or such other applicable exemption thereunder, and other applicable state securities laws.\nExcept for historical information, this news release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risk and uncertainties, which may cause but are not limited to, changing market conditions, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting.\nBRADMER PHARMACEUTICALS INC. Statements of Financial Position As at December 31 (All amounts expressed in United States dollars) 2017\n2016\nAssets Current assets Cash $ 318,879 $ 413,894 Amounts receivable 2,515 3,413 Prepaid expenses 1,259 1,176 Total assets $ 322,653 $ 418,483 Liabilities and Shareholders’ Equity Current liabilities Accounts payable and accrued liabilities $ 104,860 $ 36,759 Shareholders’ Equity Share capital 1,830,372 1,710,138 Contributed surplus 2,022,618 1,889,755 Accumulated other comprehensive income 662,594 895,332 Deficit (4,297,791 ) (4,113,501 ) Total shareholders’ equity 217,793 381,724 Total liabilities and shareholders’ equity $ 322,653 $ 418,483\nBRADMER PHARMACEUTICALS INC.\nStatements of Comprehensive Loss For the years ended December 31 (All amounts expressed in United States dollars)\n2017 2016 Expenses General and administrative $ 160,099 $ 123,000 Other (income) loss Interest (113 ) (112 ) Foreign exchange loss 24,304 12,662 Loss for the year $ (184,290 ) $ (135,550 ) Other co mprehensive loss (232,738 ) (90,236 ) Comprehensive loss for the year $ (417,028 ) $ (225,786 ) Loss per share Basic and diluted $ (0.009 ) $ (0.007 ) Weighted average number of shares outstanding 19,659,726 19,659,726\nBRADMER PHARMACEUTICALS INC.\nStatements of Changes in Shareholders’ Equity\nFor the years ended December 31 (All amounts expressed in United States dollars) Accumulated Share capital Other Total Number of Contributed Comprehensive Shareholders’ shares Amount surplus Income Deficit equity Balance, January 1, 2016 19,659,726 $ 1,659,105 $ 1,833,363 $ 985,568 $ (3,977,951 ) $ 500,085 Foreign currency translation adjustment - 51,033 56,392 (90,236 ) - 17,189 Loss for the year - - - - (135,550 ) (135,550 ) Balance, December 31, 2016 19,659,726 $ 1,710,138 $ 1,889,755 $ 895,332 $ (4,113,501 ) $ 381,724 Foreign currency translation adjustment - 120,234 132,863 (232,738 ) - 20,359 Loss for the year - - - - (184,290 ) (184,290 ) Balance, December 31, 2017 19,659,726 $ 1,830,372 $ 2,022,618 $ 662,594 $ (4,297,791 ) $ 217,793\nBRADMER PHARMACEUTICALS INC.\nStatements of Cash Flows\nFor the years ended December 31\n(All amounts expressed in United States dollars)\n2017 2016 Cash flows from operating activities Loss for the year $ (184,290 ) $ (135,550 ) Adjustments for: Foreign currency translation adjustment (5,829 ) 12,174 (190,119 ) (123,376 )\nChange in non-cash operating items Amounts receivable 898 1,685 Prepaid expenses (83 ) 92 Accounts payable and accrued expenses 68,101 9,720 (121,203 ) (111,879 ) Effect of exchange rate fluctuations on cash held 26,188 5,015 Decrease in cash (95,015 ) (106,864 ) Cash at beginning of year 413,894 520,758 Cash at end of year $ 318,879 $ 413,894\nSource:Bradmer Pharmaceuticals Inc.", "external_links": ["https://www.globenewswire.com/Tracker?data=9XSWP5Cp7VLGiDrqHLIuDdJRCITitJBXJFgLx8xlCHwbjT4YGQ2crfKATjgtcibW0SDBzbzxw2J88EhJ9UbfMQ==", "https://www.globenewswire.com/Tracker?data=25KRpjLr9UmclEoKDMRNA_jS4xNPTC6hlXjbHKQZxnUvV4QMZetwJzErcnDdoaPA5T4SbOLS-CqSRGmx5b39UA==", "https://www.globenewswire.com/NewsRoom/AttachmentNg/48ea1a5d-1705-42a2-95f0-3c00906bf5b8", "https://www.globenewswire.com/Tracker?data=45MqRtBrpd3-8PwvRWNWBWsdv6rqkfIvzOn_E2EhpKgw5gGtj_cXWwD9xRwuVKVy_Oo13u-ZcijoPkvTj9HAXUEw8vDNq9ccgnfWid-2g8Y="], "published": "2018-04-05T00:00:00.000+03:00", "crawled": "2018-04-05T03:04:07.001+03:00", "highlightTitle": ""}